Efficacy of entecavir for 96 weeks in patients with hepatitis B virus-related cirrhosis and chronic hepatitis B

Objective To compare the antiviral efficacy of entecavir for 96weeks in patients with hepatitis B virus-related cirrhosis and chronic hepatitis B.Methods A total of 160cases were collected,including 71patients with hepatitis B virus-related cirrhosis and 89patients with chronic hepatitis B,who had not previously received a nucleoside analogue,all the patients received 0.5 mg of entecavir once daily for 96 weeks.Virological,serological,biochemical markers,prothrombin time,Child-Pugh scores and renal function were observed at different time during the course of therapy.Results ①The levels of HBV DNA and ALT decreased obviously,and the number of patients with HBeAg seroconversion increased gradually after ETV therapy in both groups,however there were no significant difference between two groups at different time.② With the treatment prolonged,the serum albumin,total bilirubin,and prothrombin time were improved to some extent in both groups.The serum albumin,total bilirubin,prothrombin time and Child-Pugh score were markedly higher at week 48and 96compared with their baseline statistically.By group analysis,the increased margins of serum albumin,the decreased margins of total bilirubin,prothrombin time,ChildPugh score from the baseline were the highest in the decompensated cirrhosis group and higher in the compensated cirrhosis group than the chronic hepatitis group.③There was no evidence of serum creatinine increasing above the upper limit of normal during treatment in two groups.Conclusion The antiviral efficacy in patients with hepatitis B liver cirrhosis and chronic hepatitis B on virology,serology and biochemical responses are similar by entecavir.Meanwhile,antiviral treatment can improve hepatic reserve at all stages and was most beneficial and significant for decompensated cirrhosis.